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Case presentation
A 41-year-old man was admitted to the Fundación Jiménez Diaz
Hospital because of progressive renal failure with proteinuria. Four years
before, he had been evaluated by a nephrologist because of microscopic
hematuria and hypertension. At that time, the serum creatinine and
creatinine clearance were 1.2 mg/dl and 90 mI/mm, respectively; protein
excretion was 450 mg/24 hr. A renal ultrasonographic examination was
unremarkable. The patient refused a renal biopsy, and the diagnosis of
chronic glomerulonephritis was made. Nifedipine, 20 mg twice daily, was
prescribed.
In the 2 years before admission, the patient developed progressive
deterioration of renal function with increasing proteinuria. The serum
creatinine 18, 10, and 2 months before admission was 1.5, 1.8, and 2.0
mg/dl, respectively. Values for creatinine clearance were 84, 71, and 60
mi/mm, and the protein excretion rates were 2.5, 3.2, and 3.8 g/24 hr,
respectively.
The patient had no history of hepatitis, diabetes, or lung or heart
disease. He smoked 3—4 cigarettes per day and drank alcohol only
occasionally. He was not compliant with a sodium-restricted diet and
remained hypertensive. Medications at the time of admission included
nifedipine, 40 mg daily, and hydrochlorothiazide, 50 mg every second day.
Physical examination revealed a well-developed white man. The blood
pressure was 163/1 12 mm Hg; pulse, 83 heats/mm; temperature, 36.8°C;
and weight, 73 kg. Minimal peripheral edema in his lower extremities was
the only positive physical finding. No signs or symptoms of a systemic
disease were present.
Relevant laboratory values on admission were: serum ercatinine, 2.1
mg/dl; creatinine clearance, 58 mI/mm; serum albumin, 3.0 g/dl; and serum
cholesterol, 284 mgldl. Urinalysis disclosed a pH of 6.2, specific gravity of
1.020, and 4+ protein. The urine sediment contained 40—50 red blood
cells/high-power field and some granular casts. The protein excretion rate
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was 4.28 g124 hr. Several immunologic tests, including ANCA, ANA,
complement, HB5Ag and immunoglobulins, were normal; serum IgA level
was slightly increased at 306 mgldl.
A percutaneous renal biopsy showed moderate focal and segmental
mesangial proliferation, with scattered areas of interstitial inflammatory
cell infiltrates and sclerosis. Neither crescents nor evidence of vasculitis
was noted. Immunofluorescent study showed diffuse granular staining for
IgA and C3 in the mesangium, with no significant glomerular staining for
IgG, 1gM, flbrinogen, or albumin. The pathologic diagnosis of IgA
nephropathy was made. The patient was treated with a sodium-restricted
diet and enalapril, 40 mg daily.
He was reevaluated one month after the renal biopsy was performed.
The blood pressure was 123/84 mm Hg, and the physical examination was
unremarkable. His only medication was enalapril, 40 mg daily. The serum
creatinine and creatinine clearance were 2.2 mg/dl and 53 mI/mm,
respectively. The protein excretion rate was 1.94 g/24 hr. At his last
examination, 24 months after renal biopsy, he remained normotensive,
with a serum creatinine of 1.95 mg/dl; creatinine clearance, 59 mI/mm; and
protein excretion rate, 1.84 g/24 hr.
Discussion
DR. JESeS EGID0 (Associate Chief of Nephrology, Fundación
Jiménez DIaz, and Associate Professor of Medicine, Autonoma
University, Madrid, Spain): This patient exemplifies the major
importance of management of systemic hypertension in the
long-term maintenance of renal function in patients with IgA
nephropathy. The decline in proteinuria and the stabilization of
renal function following treatment with an angiotensin-convert-
ing-enzyme (ACE) inhibitor is consistent with recent short-term
trials [1—3] indicating that ACE inhibition has a specific benefit in
these patients, similar to that observed in experimental models of
glomerular hypertension and in patients with diabetic nephropa-
thy [4—6].
Several recent findings have heightened the interest of clini-
cians and researchers in the role of angiotensin II (Ang II) [7].
These findings include the ability of ACE inhibition to slow the
progression of renal failure in normotensive patients [8] (without
causing a detectable fall in blood pressure), evidence showing that
Ang II is a growth modulator [9], better knowledge of the local
renin-angiotensin system [10, 11], and the availability of specific
Ang II receptor antagonists [12]. Moreover, the isolation of
endothelin (ET-1) from cultured supernatant of porcine endothe-
hal cells [13], the demonstration of its secretion by renal cells [14],
and its potential implication in inflammation and glomerular
injury [15, 16] have raised enormous interest in this newer potent
vasoconstrictor hormone.
In this Nephrology Forum, I will review the most recent
understanding of the local renal actions of Ang II and endothelins
and explore how both vasoactive peptides could be implicated in
tissue remodeling and renal sclerosis (Fig. 1). I also will discuss
the evidence suggesting that the pharmacologic blockade of
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endogenous generation of these substances, or the employment of
specific receptor antagonists, could act beneficially by modulating
their growth-promoting and matrix-regulating effects in experi-
mental and human renal disease.
Angiotensin
Renin-angiorensin system and the kidney. I will first discuss
angiotensin, then move on to endothelin and conclude by consid-
ering interactions between Ang II and endothelin. The renin-
angiotensin system traditionally has been regarded as the princi-
pal regulator of intravascular volume and systemic blood pressure.
Originally defined as an endocrine system, recent data suggest
that it also functions at the autocrine-paracrine level [reviewed in
10, 11]. Components of the renin-angiotensin system are present
in many tissues, and the evidence for local Ang II biosynthesis is
compelling. While the physiologic function of the locally acting
renin-angiotensin system remains a subject of active investigation,
this tissue-based system can be regulated independently of the
endocrine renin-angiotensin system. Some investigators have sug-
gested that the plasma renin-angiotensin system is predominantly
important for acute regulatory mechanisms, whereas the tissue
renin-angiotensin system might be more involved in chronic
aspects of renal vascular regulation [10, 111. We now know that
plasma renin activity does not reflect intrarenal Ang II produc-
tion; the concentration of this hormone is one thousand times
higher in the kidney than in plasma [17]. Locally generated Ang II
could bind to receptors of the glomerulus and cause constriction
of mesangial cells and of the afferent and efferent arterioles,
thereby altering the glomerular ultrafiltration coefficient. The
magnitude of the constrictor effect of Ang II on these targets is
not uniform among different pathophysiologic states; the reasons
for this are unknown [7].
The genes of all renin-angiotensin system components have
been cloned, and several studies have investigated the gene
expression and regulation of tissue renin, angiotensinogen, and
angiotensin-converting enzyme in physiologic and pathophysio-
logic settings in the kidney. However, most of these studies have
been carried out in animals, and little is known about the
expression and regulation of these compounds in humans. By
means of a sensitive, competitive polymerase chain reaction
(PCR), Paul et al recently demonstrated that renin, angiotensino-
gen, and angiotensin-converting enzyme are present both in the
cortex and medulla of human kidneys [18].
Two major and distinct Ang II receptors have been identified:
AT1 and AT2; both receptors have been cloned recently [12]. In
rodents, cloned subtypes of AT1 receptors, designated AT1 and
ATIb, exist, but they have not been functionally distinguished in
the kidney. The ratio of AT1/AT2 varies from species to species
and from tissue to tissue within the same species. In fetal human
kidneys, AT2 predominates, whereas in the adult human kidney,
AT1 is more abundant. A recent study found, however, that only
AT1 receptors were present in human fetal mesangial cells in vitro
[19]. Today it seems clear that most of the known effects of Ang
II, especially in humans, are AT1-mediated. However, recent
experiments suggest that the AT2 receptor also might have a
functional role in the kidney. Dzau et al speculated that the AT2
receptor mediates antiproliferative rather than proliferative ef-
fects [12]. In coronary endothelial cells, the antiproliferative
actions of the AT2 receptor offset the growth-promoting effect
mediated by the AT1 receptor [201. Thus, the two receptors might
mediate counterbalancing signals [12]. Both AT1 and AT2 could
be important in endothelial cells and fibroblasts, two important
targets for Ang II in renal disease [21]. When Ang II binds to AT1
receptors, it stimulates the hydrolysis of phosphatidylinositol
4,5-biphosphate, yielding two second messengers, inositol 1,4,5-
triphosphate (1,4,5-IP3) and diacylglycerol. The 1,4,5-1P3 mo-
bilizes intracellular stores of calcium, whereas diacylglycerol
simulates protein kinase C. Angiotensin II stimulates tyrosine
phosphorylation of phospholipase C-gammal; this finding further
supports the idea that this event could be responsible for early
signal transduction [221. By contrast, the AT2 could belong to a
unique class of seven-transmembrane domain receptors for which
G protein coupling has not been demonstrated [23].
Ang II as a growth factor for renal cells. Expansion of the
mesangium, due to proliferation or hypertrophy of mesangial cells
and an increase in extracellular matrix, is the hallmark of a
number of inflammatory and noninflammatory glomerular dis-
eases [24]. However, the exact cellular mechanisms responsible
for mesangial cell proliferation and hypertrophy have not yet been
defined. Most of our knowledge about Ang II as a growth factor
comes from studies of its effects on vascular smooth muscle cells
[25—28]. Indeed, several lines of evidence suggest a role for the
renin-angiotensin system in the vascular smooth muscle cell
growth that occurs as a consequence of hypertension, vascular
injury, or atherosclerosis. Preliminary work showed that in the
presence of serum, Ang II promotes hyperplasia [291 but that in
the absence of serum, Ang II induces only hypertrophy [30].
Recent experiments have demonstrated that Ang II is a bifunc-
tional modulator of vascular smooth muscle cell growth, which is
capable of inducing hypertrophy or inhibiting mitogen-stimulated
DNA synthesis [27]. Stimulation of those cells by Ang II increases
Glomeruloscierosis
Fig. 1. Hemodynamic and nonhenodynamic glomerular actions of Ang II
and ET-1. All the phenomena described in this figure have been demon-
strated for Ang II. By contrast, some of them (the effects of ET-1 on GBM
permeability or mesangial cell hypertrophy) are suspected but not proved.
580 Nephrology FonLm: Vasoactive hormones and renal sclerosis
AngIl/ET-1
__ __
1
TGFf31
Jr
the production of presumed autocrine factors such as transform-
ing growth factor 13 (TGFI31), platelet-derived growth factor
(PDGF), and basic fibroblast growth factor (bFGF); thus Ang II
might affect cell growth indirectly. In particular, TGFI31 appears
to be pivotal in the regulation of Ang IT-induced hypertrophy
versus proliferation of smooth muscle cells. Furthermore, TGF/31
modulates the mitogenic actions of bFGF and PDGF. Although
TGFJ3, is antimitogenic for some tissues [10, 27, 311, it promotes
proliferation in smooth muscle cells via both PDGF-AA-depen-
dent and PDGF-AA-independent mechanisms [32]. Angiotensin
II also induces the release of other potential growth factors, JL-6,
endothelin, and platelet activating factor (PAF). An imbalance of
these growth factors can promote Ang lI-mediated cell prolifer-
ation (Fig. 2). Mechanical strain and collagen potentiate mito-
genic activity of Ang II in rat vascular smooth muscle cells. The
synergy between Ang II and strain was completely eliminated by
neutralizing antibodies to PDGF AB [33]. A similar mechanism
could possibly work in mesangial cells, in which stretching stimu-
lates proliferation and extracellular matrix formation [34, 351.
Thus, the addition of Ang II augmented stretch/relaxation-in-
duced rat glomerular mesangial cell proliferation and production
of noncollagenous proteins [35].
The growth effect of Ang II on mesangial cells and on tubular
epithelial cells has been studied by various investigators [reviewed
in 9, 36]. Hypertrophy or proliferation has been reported after
Ang II stimulation of mesangial cells from different species
(Table 1). For example, Wolf et al observed that in a simian-virus-
transformed murine mesangial cell line, Ang II induced prolifer-
ation in a dose-dependent manner in serum-free media, an effect
that was transduced by AT1 receptors [37]. Similar results were
obtained by Ray and colleagues in human fetal mesangial cells
[19]. Although the degree of proliferation may be modest in
Origin of cells Cell growth Matrix
Fujiwara et al [226]h Rat Proliferation Fibronectin
Homma et al [227] Rat Hypertrophy Collagen
Wolthuis et al [228] Rat Proliferation Fibronectin
Wolf et al [37] Murine cell line Proliferation Collagen I
Anderson et a! [38] Mouse Hypertrophy NDC
Ruiz-Ortega et al [50] Rat Proliferation Fibronectin
Ray et al [19] Human fetus Proliferation
Collagen IV
Fibronectin
Fibronectin
Biglycan
Kagami et al [31] Rat Hypertrophy Collagen I
Orth et a! [229] Human adult Proliferation
Hypertrophy
ND
C The conflicting results reported may be due partly to the different
origin of cells (rat, murine, human), and variable culture conditions
(primary culture with low or multiple passages, degree of confluence,
timing of the study, 28 versus 72 hours). Due to space limitations, only
selected references are included.
h Numbers in brackets are reference numbers.
C ND = not done.
comparison with that obtained with a growth factor like PDGF, a
discrete mesangial cell proliferation is usually observed in some
types of glomerulonephritis. By contrast, other authors have
found that Ang 11-treated mesangial cells showed hypertrophy but
not proliferation [31, 38] (Table 1). Under most conditions in
cultured vascular smooth muscle cells, Ang II induces both
proliferation mediated by bFGF and PDGF and an antiprolifera-
tive pathway mediated by TGFI31 [10, 27]. On balance, a hyper-
trophic response occurs. Under some tissue culture conditions,
Direct
effect
1
V
bFGF
PDFG
Jr
I L-6
PAF
Arachidonic acid
derivates
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[ Hyperplasia / Fig. 2. Ang II and ET-1 as growth factors for
mesangial cells.
Table 1. Angiotensin II, mesangial cell growth, and matrix proteinsa
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however, an imbalance between the proliferative and antiprolif-
erative signals produces cellular hyperplasia [10]. Whether a
similar phenomenon exists in glomerular mesangial cells is un-
known. However, when Ang II and neutralizing antibodies to
TGFf3, were combined, cell proliferation increased significantly;
this finding is consistent with the idea that TGFI31 influences the
biologic actions of Ang II [311. Aproliferative synergy also occurs
with other growth factors, such as epidermal growth factor (EGF)
[39, 40]. Furthermore, stretch or tension alters vascular tone as
well as structure. Increased tension promotes the generation of
vasoconstrictors and mitogenic factors such as endothelium-
dependent contracting factors and PDGF, as well as matrix
modulators such as collagen [41].
The cellular mechanisms involved in Ang IT-stimulated mito-
genesis are poorly defined and may be distinct from those of other
mitogenic agents. Recent data have shown that although Ang II
stimulates acute expression of c-fos to a similar degree as mito-
genic concentrations of fetal bovine serum or PDGF-BB, Ang
Il-stimulated DNA synthesis is delayed. This delay might ensue
because increased expression of new gene products is required
before initiation of DNA synthesis [42]. Angiotensin II, like other
vasoactive agents, induces the expression of immediate early
genes in cultured mesangial cells, vascular smooth muscle cells,
and cardiomyocytes. Perfusion of rat kidneys in vivo with Ang II
also induced expression of the proto-oncogenes c-fos and Egr-1
[43—45]. It is reasonable to speculate that some of the growth-
stimulatory effects of Ang II on mesangial cells involve an
autocrine activation of those factors.
Contrasting with the dual effect of Ang II on mesangial cells
(hypertrophy versus hyperplasia), Ang II induced only cellular
hypertrophy, not proliferation, in viral-transformed murine prox-
imal tubular cells, a permanent porcine tubular epithelial cell line
(LLC-PK1) [36, 46, 47] and in rabbit proximal tubular cells [48].
Although this effect was mediated through AT1 receptors, Ang II
did not stimulate the phosphatidylinositol pathway in murine
proximal tubular cells, and the hypertrophy seems to be mediated
by a decrease in cAMP. It is interesting that Ang II stimulated an
S6 kinase in these cells, which in turn phosphorylated a ribosomal
protein and increased protein synthesis [48]. However, Ang II
increased the mitogenesis induced by EGF in cultured primary
rabbit proximal tubular cells [49].
Ang II and extracellular matrbc. In the glomerulus, the main
contributors to matrix accumulation are mesangial and epithelial
cells. Immunofluorescence studies have revealed that the major
constituents of the mesangial matrix are collagen types IV and V,
the glycoproteins laminin and fibronectin, and the proteoglycans
heparan sulfate (perlecan) and chondroitin/dermatan sulfates
(versican, dccorin, and biglycan), all of which are synthesized by
mesangial cells in culture. In certain culture conditions, and in
pathologic settings, mesangial cells also synthesize relatively large
amounts of the interstitial collagens (types I and III).
Several studies have demonstrated that Ang II stimulates the
synthesis of structural components of the extracellular matrix in
mesangial and smooth muscle cells in vitro [9, 19, 31, 37]. An
increase in the glomerular accumulation of fibronectin and colla-
gens, which produces fibrosis, has been observed in a variety of
settings associated with mesangial proliferation [241. Most of
these studies, including our own, have demonstrated that Ang II
induces an increase in the expression and synthesis of fibronectin
in a dose- and time-dependent manner. In cultured murine
mesangial cells, Ang II also stimulates the transcription and
biosynthesis of collagen type I, but not type IV. However, rat
mesangial cells produce large amounts of collagen IV when
stimulated by Ang II [50, 51]. Subpressor doses of Ang II also
stimulate vascular glycosaminoglycan synthesis [52].
Although the precise mechanisms leading to matrix expansion
are not known, evidence suggests that cytokines, growth factors,
and vasoactive hormones play a significant role. Among the
different growth factors stimulated by Ang II, TGFI31 has a major
role in regulating extracellular matrix turnover. TGFj31 stimulates
matrix protein synthesis (fibronectin, collagens, and laminin) and
inhibits matrix degradation both by increasing the activity of
protease inhibitors and by decreasing proteases, and it stimulates
the synthesis of matrix protein receptors such as integrins [53].
Also, TGFI31 is a chemoattractant for fibroblasts and stimulates
fibroblast proliferation. Recent data, chiefly accumulated in the
rat anti-Thy-i nephritis model, have demonstrated that TGFp1 is
a critical determinant of in-vivo matrix accumulation [54]. Sus-
tained TGF/31 expression contributes to the development of
progressive renal fibrosis [55]. Using in-vivo gene transfection,
Isaka et al demonstrated definitive evidence of the involvement of
TGFp, in the increase of renal matrix; they confirmed that TGF/31
can produce marked glomeruloscierosis by itself [56]. As in
vascular smooth muscle cells, Ang II increases the level of TGF/31
mRNA and the production of both latent and active TGF/31 in rat
mesangial cells [31]. The presence of anti-TGFj31 antibodies also
decreases the synthesis of matrix in cultured mesangial cells [50].
These data are consistent with the hypothesis that Ang II's effects
on matrix protein synthesis are, at least in part, indirect and
depend on autocrine secretion of TGF/31 and other growth
factors. Those data support the existence of a molecular cascade
in which Ang II stimulates the production and secretion of active
TGFI31, which in turn stimulates the synthesis and deposition of
matrix components. This pathway is probably not unique for Ang
II. We recently demonstrated that activation of Fc receptors in
mesangial cells increased the expression and synthesis of matrix
proteins, which was preceded by the expression and synthesis of
TGFI31 [57]. We observed a similar phenomenon with platelet
activating factor. We also demonstrated that this lipid induces
matrix and TGF/31 expression in rat mesangial cells [58]. Angio-
tcnsin II also stimulates the transcription and synthesis of type-lV,
but not of type-I, collagen in cultured proximal tubular cells [46].
A CE inhibitors and Ang II antagonists in experimental and
human renal disease. The role of ACE inhibitors in renal disease
was reviewed in a previous Nephrology Forum [59]. Therefore,
here I will discuss ACE inhibitors only briefly. The model most
frequently employed to assess the role of ACE inhibitors is the
marked reduction of renal mass in rats, which induces proteinuria,
hypertension, and progressive renal insufficiency associated with
glomerular sclerosis [60]. Studies have found increased renal
plasma flow and glomerular capillary pressure in the remnant
nephrons [59, 61]. In this model, ACE inhibitors have a protective
effect on renal function that is associated with normalization of
the glomerular capillary pressure, probably as a result of the
attenuation of Ang II's effects on the glomerular afferent and
efferent arterioles. Some [62, 631, but not all [64], investigators
conclude that ACE inhibitors are more effective in preventing the
functional damage in this model than is conventional treatment
a
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Fig. 3. Effect of ACE inhibitors on glomerular
damage and immune-complex nephritis. A,
glomerulus of a nephritic rat showing the
expansion of the mesangial area, cellular
proliferation, and sclerotic lesions. B, in
quinapril-treated rats, only a slight mesangial
expansion was observed.
with triple therapy (reserpine, hydralazine, and hydrochlorothia-
zide), in spite of an equivalent reduction in arterial blood pres-
sure.
Angiotensin-converting-enzyme inhibitors are effective in other
experimental models of renal injury, namely, unilateral nephrec-
tomy in spontaneously hypertensive rats (SHR), one-clip Gold-
blatt-type hypertension induced after unilateral nephrectomy,
puromycin-induced nephrotic syndrome, and Heymann nephritis
[reviewed in 59]. Kiyama and colleagues recently showed that
enalapril suppressed mesangial cell proliferation and mesangial
expansion in SHR with anti-thymocyte serum-induced nephritis
[65].
In our studies, we have explored the effect of the ACE inhibitor
quinapril in normotensive rats with chronic glomerulonephritis, a
disease characterized by the presence of immune complexes in all
areas of the glomerulus, intense cell proliferation, and mesangial
matrix expansion [66, 67]. This rat model resembles diffuse
proliferative lupus nephritis in humans. Untreated rats developed
massive nephrotic syndrome and renal failure approximately 3
weeks after the onset of proteinuria, whereas quinapril-treated
rats experienced no significant increase in proteinuria, and renal
function was preserved. Morphologically, quinapril-treated rats
had less glomerular hypercellularity, glomerulosclerosis, and tu-
bular and interstitial lesions than did untreated rats (Fig. 3). The
gene expression of fibronectin and collagens IV, I, and III in the
renal cortex decreased between 40% and 80% in rats treated with
quinapril. Blood pressure was normal both in treated and un-
treated animals during the study. These data show that early ACE
inhibitor administration in normotensive rats with immune-com-
plex nephritis prevents proteinuria, glomerular lesions, and an
increase of matrix proteins, probably by modulating the effect of
Ang II on the synthesis of growth factors and matrix proteins. This
study therefore provides strong evidence for the use of ACE
inhibitors in patients with immune-complex nephritis with overt
glomerular damage, even in the absence of systemic hypertension.
For many years we have known that untreated or poorly treated
hypertension accelerates the progression of renal failure. Like-
wise, good control of arterial pressure delays this progression. In
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recent years considerable attention has been paid to the potential
benefits of ACE inhibitors in renal diseases beyond simply their
control of blood pressure. Several studies, most of them short
term, have demonstrated that these drugs diminish proteinuria
and protect renal function in different glomerulopathies, even in
patients without hypertension [68—70]. Recently, studies have
been performed for longer periods and in patients with nephrotic-
range proteinuria [70, 71]. Praga et al studied a group of 46
nondiabetic patients with substantial proteinuria who were
treated with captopril for a minimum of 12 months and observed
a mean decrease in proteinuria of approximately 45%. For
unknown reasons, patients with massive proteinuria and normal
serum albumin responded better than did those with hypoalbu-
minemia [72]. The greater beneficial effect was seen in patients
with a variety of renal problems including a substantial reduction
in renal mass, IgA nephropathy, nephrosclerosis, and chronic
glomerulonephritis with inactive crescents.
Diabetic nephropathy deserves particular attention. The exis-
tence of marked glomerular hyperfiltration in the early phase of
diabetes suggested that ACE inhibitors could be particularly
useful in this situation. In fact, several studies in the 1980s strongly
suggested that these drugs diminished proteinuria and retarded
the rate of decline in glomerular filtration rate in those patients
[73—75]. Mimran and colleagues observed in normotensive ne-
phrotic patients with incipient diabetic nephropathy that the
administration of nifedipine increased proteinuria, but captopril
diminished it [8]. In the most complete work on this subject,
Lewis et al compared 207 patients receiving captopril with 220
who were given a placebo; the ACE inhibitor significantly delayed
the rate of loss of renal function [6]. The risk of doubling the
serum creatinine concentration was reduced almost 50%. A
similar reduction was noted in the combined risks of death and
renal replacement therapy by dialysis or transplantation. Because
the extent of the reduction in arterial blood pressure in the two
groups was comparable, this study supports the hypothesis that
ACE inhibitors diminish the progression of diabetic nephropathy
by a mechanism independent of its antihypertensive properties.
An important question in the pharmacology of inhibition of the
renin-angiotensin system is whether Ang II antagonists and ACE
inhibitors have identical effects or whether they can be differen-
tiated. Theoretically, the AT1 antagonist provides better block-
ade. By contrast, ACE inhibition has additional actions apart from
the inhibition of Ang II production. So far, however, both classes
of compounds appear to have similar systemic and regional
hemodynamic effects on the kidney [76]. As has been seen with
ACE inhibitors, Ang II receptor antagonists also have beneficial
effects in experimental renal diseases. Micropuncture studies have
shown that glomerular transcapillary pressure was reduced signif-
icantly by either type of drug in a 5/6th ablation model. Both
enalapril and the Ang II receptor antagonist DuP753 decreased
proteinuria and segmental glomerular sclerosis [77]. Pollock et a!
made similar observations employing two different Ang II recep-
tor antagonists [78].
Less information is available regarding Ang II receptor antag-
onists in human renal disease. Gansevoort and colleagues em-
ployed losartan, the only AT1 antagonist available for clinical use,
in 11 hypertensive patients with renal disease [79]. The reductions
in blood pressure, proteinuria, and filtration fraction were similar
to those induced by the ACE inhibitor enalapril in the same
patients. This study thus supports the hypothesis that the benefi-
cia! renal effects of these drugs are primarily mediated by inter-
ference with the renin-angiotensin system. Direct comparative
clinical studies are needed to show whether a practical difference
exists between ACE inhibitors and Ang II antagonists in the
treatment of patients with progressive renal disease.
Mechanisms of action of ACE inhibitors in renal disease. Most
clinical investigators believe that ACE inhibition has a beneficial
influence on the altered glomerular hemodynamics in diabetic
patients and in patients with reduced renal mass. In diabetic
animals, the efferent glomerular tone is increased and, as a
consequence, an increase in the hydraulic transcapillary pressure
is produced that can reduce the functional integrity of the
glomerular capillary wall. The suppression of the constrictive
effect of Ang II on the efferent arterioles reduces glomerular
pressure without modifying renal plasma flow [80, 811.
Several studies have demonstrated that ACE inhibitors improve
the size-selective properties of the glomerular membrane, reduc-
ing the average diameter of the nonselective big pores [1, 82].
Although the mechanisms of this effect are unknown, it is possible
that the prevention of mesangial cell contraction induced by Ang
II could modify the pore size of the glomerular capillary filter.
This phenomenon could be independent of the hemodynamic
changes and might explain the reduction in proteinuria.
Angiotensin-converting-enzyme inhibitors also might decrease
renal damage by modifying the proliferative effects of Ang II.
Thus, the infusion of this hormone for 7 days to healthy rats
induced moderate hypertension; marked glomerular, tubulointer-
stitia!, and vascular damage; proliferation of resident glomerular
and interstitial cells; and recruitment of inflammatory cells [83]. In
the 2-kidney, one-clip Goldblatt model of renovascular hyperten-
sion, early tubular cell proliferation, infiltration of mononuclear
cells, and an increase in matrix protein deposition, predominantly
in the renal interstitium, were observed [84]. Both Ang II and Ang
III, a heptapeptide derived from Ang II through the action of
aminopeptidases, are chemoattractants for leukocytes [7, 85].
The angiotensin-converting enzyme, a dipeptidyl carboxypepti-
dase, plays a central role in both the renin-angiotensin and
kallikrein-kinin systems by activating the conversion of Ang I to
Ang II and inactivating bradykinin. Bradykinin produces prolifer-
ation of cultured mesangial cells [86], although proliferative as
well as antiproliferative effects have been shown in smooth muscle
cells. Also, ACE inhibitors stimulate the formation of nitric oxide
and prostacyclin, most likely by inhibiting the breakdown of
bradykinin. The beneficial effect of ACE inhibitors might be
mediated by nitric oxide, a known inhibitor of smooth muscle cell
mitogenesis and proliferation [87]. The inhibitory effect of capto-
pril on collagenases that can degrade type-TV collagen might
partially explain the reduction in proteinuria observed with this
class of compounds [88].
The renin-angiotensin system and renal interstitial fibrosis. We
have known for years that progressive renal disease is accompa-
nied by an interstitial infiltrate of mononuclear cells that precedes
and accompanies tubular atrophy and interstitial fibrosis. In fact,
the progression of the many different forms of glomerulonephritis
is determined more by the degree of tubulointerstitial injury than
by the extent of the glomerular involvement. Some investigators
have suggested that the inflammatory cell renal interstitial infil-
trates could lead to tubular atrophy and interstitial fibrosis
through the secretion of cytokines and growth factors [89], which
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in turn would stimulate interstitial fibroblasts to proliferate and to
produce matrix proteins.
Recent data suggest that the circulating and tissue renin-
angiotensin systems play an important role in interstitial fibrosis in
the kidney. Systemic infusion of Ang II for 7 to 14 days was
associated with a monocyte/macrophage influx to the kidney
followed by an increase in the synthesis of fibronectin and
interstitial collagens by the kidney [831. The accumulation of
inflammatory cells in Ang Il-induced tubulointerstitial nephritis
has been associated with osteopontin, a newly discovered inflam-
matory protein [90]. Furthermore, as I discussed earlier, glomer-
ular and tubular cells possess the complete machinery of sub-
strates and enzymes required for the synthesis of Ang II. In some
models of glomerular and vasculointerstitial disease, an increase
in some components of the renin-angiotensin system occurs [91],
yet in other models, activation of the renin-angiotensin system is
not a prominent feature despite the presence of a good response
to ACE inhibitors in this latter group. Several possibilities for this
apparent paradox have been suggested [91]. Studies of ontogeny
have clearly demonstrated that renal renin synthesis is highly
activated during early postnatal development in several species.
Angiotensin-converting-enzyme inhibition is associated with a
significant decrease in fetal renal vascular resistance and results in
glomerular growth retardation in growing rats [92].
Although the interstitial fibroblast is the principal cell impli-
cated in tissue remodeling in the kidney, scarce attention has been
paid to the Ang Il-fibroblast interaction. Just recently, however,
Villareal and colleagues showed that cardiac fibroblasts in neo-
natal rats possess functional AT1 receptors [93]. In these cells,
Ang II increased both total-protein and DNA synthesis [94, 95].
Recent data from our laboratory support the hypothesis that Ang
II directly stimulates renal interstitial fibroblasts, enhancing pro-
liferation and the synthesis of structural matrix proteins like
collagens and adhesive proteins like fibronectin (unpublished
observations). The characterization and identification of fibro-
blasts from different regions of rabbit kidney might facilitate
further studies on the potential heterogeneity of responses to Ang
II [96].
Chronic ureteral obstruction, which is followed by renal inter-
stitial fibrosis, is a good model for the participation of the
renin-angiotensin system in interstitial sclerosis [97—991 (Fig. 4).
Although various vasoconstrictors (thromboxane and renin) and
vasodilators (nitric oxide and prostacyclins) have been implicated
in the intrarenal hemodynamic alterations that take place early
after ureteral ligation, Ang II seems to play a predominant role in
the pathogenesis of fibrosis (Fig. 4). Thus, after 5 days of ureteral
obstruction, renin mRNA expression increased in the cortex and
medulla [100], and TGFI31 and collagen IV mRNA expression
increased in the cortex [98]. A downregulation of the AT1
receptor mRNA has also been reported [101]. Treatment with
enalapril during the 5 days of ureteral obstruction diminished the
TGF/31 and collagen IV expression by approximately 50% [102].
These data suggest that ACE inhibitors could decrease tubuloin-
terstitial fibrosis in the kidney by modifying the TGF1 synthesis
induced by Ang II. Diamond and Anderson reported that the
tubulointerstitial injury associated with chronic aminonucleoside
nephrosis can be prevented if Ang II generation is blocked by
ACE inhibitors [103]. Interestingly, an increase in renal TGFI3
expression was noted in adriamycin nephropathy, another model
of experimental nephrosis [104].
Fig. 4. Interstitial
obstruction.
fibrosis of the kidney. The example of ureteral
Endothelin and the kidney
Endothelin (ET-1) was first isolated from the supernatants of
cultured porcine endothelial cells in the late 1980s [13]. Subse-
quent experiments revealed that ET-1, the most potent vasocon-
strictor yet known, belongs to a family of peptides secreted by a
wide variety of cells that evoke numerous nonhemodynamic
biologic actions [reviewed in 14, 15, 105—107]. A large body of
evidence has accumulated about the mechanisms regulating ET-1
secretion, activation of ET-1 receptors, subsequent pathways of
transmembrane signaling, and possible biologic actions of ET-1 in
the kidney [reviewed in 14, 105]. The term endothelin describes a
family of 21-amino acid peptides that includes three isoforms:
ET-1, ET-2, and ET-3; they are encoded by different genes [106].
The biologic significance of these multiple endothelin isopeptides
is not yet clear, but there are significant cell- and tissue-specific
differences in isopeptide secretion and in the biologic responses to
different isopeptides. These diverse responses to endothelins
appear to be mediated by specific receptors [108].
Endothelin secretion originally was thought to be localized
exclusively in vascular endothelium, but it is now clear that
endothelin is secreted by numerous cells in the kidney and in
other organs [14, 105]. Northern blot analysis and the polymerase
chain reaction have been used to demonstrate abundant expres-
sion of prepro-ET-1 transcript in the adult kidney [109—112].
Prepro-ET-1 mRNA expression was localized in the medullaiy
vasa recta bundles and vascular sites in the cortex and medulla
[113]. Immunocytochemical studies have shown that expression of
ET-1 in the renal vasculature is not uniform and is highly
compartmentalized. Weak immunoreactivity also was observed in
the glomerular mesangium. Primary epithelial cell cultures de-
rived from different nephron segments suggest that renal tubules
secrete abundant amounts of ET-1 and lesser amounts of ET-3.
Mesangial cells in culture express a 2.3 kb prepro-ET-1 transcript
and secrete mature ET-1 peptide [114]. Macrophages also secrete
abundant amounts of ET-1 [1151; this finding suggests that
blood-borne cells might release ET-1 in response to inflammation
[15, 16]. Polymorphonuclear leukocytes cannot secrete ET-1 but
can convert non-leukocyte-derived prepro-ET-1 to the biologi-
cally active peptide.
The induction of prepro-ET-1 mRNA in endothelial cells and
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in mesangial cells is augmented by several agents such as calcium
ionophore, phorbol esters, thrombin, TGFI31 and PDGF [114]. In
supernatants of cultured rat mesangial cells, TNFs, but not IL-i,
caused a dose- and time-dependent increase in ET-1 [111].
Heparin reduced the basal and the stimulated expression of
prepro-ET-1 mRNA by thrombin and phorbol esters [116]. These
data suggest that heparin, in addition to its anti-thrombin activity,
inhibits the biosynthesis and release of ET-1, possibly by inhibiting
the protein kinase C-dependent pathway. Also, the vasoconstric-
tor hormones Mg II and arginine vasopressin induced prepro-ET-1
mRNA expression in cultured bovine carotid arterial endothelial
cells and stimulated ET-1 release through receptor-mediated
mobilization of intracellular free calcium and activation of protein
kinase C [1171.
Endothelin as a renal growth factor. Endothelin-1 induces qui-
escent mesangial cells to enter the GI phase and progress to DNA
synthesis and cell division. It is important to note that ET-1
requires either low concentrations of serum or insulin for full
mitogenic action [14, 118]. It has been demonstrated, chiefly in
smooth muscle cell culture, that ET-1 also potentiates the action
of growth factors that bind to protein tyrosine kinases, such as
bFGF and EGF [105]. Evidence also indicates that the mitogenic
action of ET-1 occurs in other renal cells such as vascular smooth
muscle cells, fibroblasts, and endothelial cells [14, 118, 119].
Although in most vascular beds the ETA receptor subtype
mediates vasoconstriction, the kidney is unique in that activation
of the ETB receptor is responsible for most of the vasoconstriction
induced by ET-1 [105]. In mesangial cells, ETB receptor activation
can induce the release of nitric oxide. The ETB receptor might
counteract the vasoconstrictive effect of ET-1 caused via ETA in
the vascular glomerulus [120]. In contrast, the ETA receptor
appears to mediate mitogenic signaling by ET-1 in glomerular
mesangial cells, as mitogenesis induced by ET-1 and ET-3 is
blocked by an ETA-specific receptor antagonist BQ123, and an
ET-specific agonist failed to stimulate cell growth [121].
Simonson demonstrated that protein kinase C inhibitors and
chronic depletion of protein kinase C with phorbol esters inhib-
ited the growth effects of ET-1, and suggested that protein kinase
C activation is required for the expression of these effects [14].
Similar to Ang II, ET-1 regulates vascular smooth muscle cell
mitogenesis through a mechanism implicating TGF!31 synthesis.
The mesangial cell proliferation elicited by ET-1 also was partially
blocked by PAF antagonists [122].
Endothelin and extracellular matris. Although it has been sus-
pected that endothelins might regulate extracellular matrix re-
modeling, no published study has fully explored this subject.
Abstract reports suggest that ET-1 increases the expression of
mRNA for collagen types I, II, and IV and laminin in rat
mesangial cells [123]. In vascular smooth muscle cells and in aorta
explants, ET-1 stimulated soluble and insoluble fibronectin syn-
thesis [124]. As with ET-1-induced proliferation, PDGF, TGFI31,
and lipid mediators appear to be involved in the regulation of
extracellular matrix by ET-1. We have demonstrated that in
cultured rat mesangial cells, ET-1 induces the expression of
fibronectin and collagen IV and the synthesis of fibronectin in a
dose-dependent manner. At equimolar concentrations, the effect
of ET-1 was greater than that of Ang II [50, 51]. Preincubation for
30 minutes with staurosporine or H-7, two different protein kinase
C inhibitors, significantly diminished the fibronectin synthesis
induced by ET-1 [501. Anti-TGFI31 antibodies also inhibited
ET-1-induced fibronectin synthesis [50].
Some of the effects of ET-1 could be due to the activation and
release of other lipid or protein mediators. For instance, ET-1
also activates mesangial cell phospholipase A2 and promotes
arachidonate release from membrane phospholipids. Arachido-
nate in turn leads to excessive formation of thromboxane A2,
which is also a stimulus for extracellular matrix protein gene
expression, and which might represent an additional pathway by
which endothelin promotes glomerular sclerosis.
Some of the effects of endothelin on renal cells also could be
due to the release of PAF. Indeed, the mesangial cell contraction
induced by ET-1 was blocked when PAF receptor antagonists
were present in the medium; ET-1 also induced in those cells a
release of PAF into the supernatant [125]. In recent experiments
we also observed that two different PAF antagonists decreased by
approximately 50% the fibronectin synthesis induced by ET-1.
Thus, at least a part of extracellular matrix production induced by
ET-1 could be due to the release of PAF. We also found that PAF
increases the expression of fibronectin, collagen I, and collagen IV
in various renal cells, and increases the release of fibronectin and
collagen into the supernatant [58].
Endothelin-1 and inflammation. The concentration of ET-1
increases significantly at sites of inflammation throughout the
body. Besides being synthesized by local renal cells, ET-l also
might be released by infiltrating macrophages [115], and prepro-
ET-1 is activated by polymorphonuclear leukocytes. A possible
role for this peptide in glomerular inflammation has been sug-
gested [15, 16]. We have shown that endothelin-i exerts various
actions on polymorphonuclear leukocytes: ET-1 elicits a transient
increase in cytosolic free calcium and increases superoxide anion
production [126]. Further studies from our group have demon-
strated that ET-1 causes aggregation of human polymorphonu-
clear leukocytes and that this effect is mediated in part through
PAF production [127].
Circulating ET-1 levels are elevated in conditions other than
classical inflammation. Recent studies have shown that circulating
immunoreactive ET-1 levels also are elevated in atherosclerosis, a
condition in which the interaction between the polymorphonu-
clear leukocytes and the endothelium is especially important [128,
129]. In this setting, ET-1 probably causes polymorphonuclear
leukocyte adhesion to the endothelium. This effect might be
mediated by CD11b and CD18 antigens, because adhesion was
blocked by TS1/18, an antibody against those molecules [130].
Furthermore, flow cytometry studies have shown that ET-1 aug-
mented the surface expression of the CD11b-CD18 antigens.
Moreover, we recently found an effect of ET-1 on polymorpho-
nuclear leukocyte accumulation in the heart and kidney in in-vivo
experiments [1301. Therefore, I believe it likely that ET-1 could
participate in the first phases of polymorphonuclear leukocyte
recruitment at the tissue level. The close relationship between
ET-1 and inflammatory cytokines also might be important for the
pathogenesis of inflammation [111, 114].
Endothelin and renal disease progression. Besides the vasoactive
properties of eridothelin, this hormone induces mesangial cell
proliferation and synthesis of matrix proteins (Fig. 1). It therefore
has been suspected that ET-i synthesis or metabolism might be
altered in chronic renal damage and that this alteration possibly
contributes to maintaining glomerular ischemia, mesangial cell
proliferation, and accumulation of matrix proteins [16, 131, 132].
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The issue of whether increased ET-1 synthesis occurs in vivo has
been investigated in a wide range of experimental glomerular
diseases. In rats after renal mass ablation, urinary ET-1 excretion
increased progressively with time after surgery, paralleling the
degree of glomerular injury [133]. Northern blot analysis in kidney
homogenates showed a 2.5-fold and 4.0-fold increase in pre-
proET-1 transcript at 30 and 120 days, respectively. Furthermore,
isolated glomeruli from animals with renal mass reduction gener-
ated more ET-i than did control kidneys [134]. Treatment with
the ETA receptor antagonist FR139317 prevented mesangial
hypercellularity and decreased segmental glomerulosclerosis
[1351. The finding that the ETA receptor antagonist suppressed
upregulation of c-fos proto-oncogene expression in rats with renal
mass reduction offers a biochemical basis for interpreting the
prevention of mesangial cell proliferation and renal disease
progression. In another model of glomerular injury induced by
puromycin aminonucleoside injection, glomerular endothelin ex-
pression was increased during the 80 days of study, the levels
correlating well with the percentage of sclerotic glomeruli [136].
In lupus NZBIWR1 mice, renal levels of ET-1 mRNA increased
significantly as their nephritis progressed; at 24 weeks, the ET-1
mRNA concentration was tenfold higher than that in control
NZB/WF1 mice [1371. By contrast, ET-3 mRNA levels remained
unchanged. The values of ETA and ETB receptor mRNA in-
creased gradually with the progression of nephritis. Treatment
with methylprednisolone was accompanied by a reduction in
mRNA levels for ET-1 and ET receptors [1371. In that study, prior
to steroid therapy, renal TNFa and ET-i mRNA levels increased
in parallel with the progression of lupus nephritis; this finding
suggests that after stimulation by cytokines, ET-1 might signifi-
cantly modulate renal damage. Moreover, we know that TNFo
stimulates ET-1 production in glomerular capillary endothelial
cells and mesangial cells in vitro [111, 138]. Yoshimura et al noted
an upregulation in the glomerular expression of ET-1 protein,
ET-1 mRNA, and ET receptor in yet another experimental
glomerular disease, rat mesangial proliferative nephritis induced
by anti-Thy-i antibodies [139]. The administration of a specific
ETA receptor antagonist prevented the renal injury in lupus
NZB/WF1 mice and attenuated the extracellular matrix accumu-
lation in renal cortex [140].
We also have explored the idea that ET-i could participate in
glomerular injury in an immune-complex nephritis model in the
rat. We found an increase of prepro-ET-1 gene expression even in
the mild phase of nephritis. This level of expression was more
marked in the severe phase and coincided with maximal mesangial
cell proliferation, leukocyte infiltration, and matrix accumulation;
the urinary excretion of ET-1 also was increased (unpublished
observation).
Nakamura and colleagues noted that, in most patients with IgA
nephropathy, circulating monocytes expressed ET-1 mRNA [141].
By contrast, no ET-1 mRNA expression was noted in monocytes
from 40 patients with other forms of glomerulonephritis, including
some with heavy proteinuria, mesangial proliferation, or both
[141]. These researchers noted that in the patients with IgA
nephropathy, a good correlation existed between ET-1 mRNA
expression and glomerular damage, as assessed by proteinuria and
renal function. These authors speculated that ET-1 secreted by
circulating monocytes probably could reach the glomerulus, inter-
stitium, or blood vessel wall [141].
A relationship also has been noted between elevated circulating
levels of ET-1 and severity of diabetic nephropathy. The secretion
of ET-1 is increased by high glucose levels in the media of
cultured bovine aortic endothelial cells [142]. A high glucose
concentration downregulates ET-1 receptor levels in cultured rat
mesangial cells [143]. Recently, Fukui and coworkers demon-
strated that ET-1 mRNA levels in glomeruli of diabetic rats
increased in parallel with the progression of nephropathy [144]. In
contrast, ETA and ETB receptor mRNA levels were not altered in
the glomeruli from diabetic and control rats throughout the
experimental period. Insulin treatment decreased glomerular
ET-i mRNA. These findings indicate that increased ET-1 mRNA
in glomeruli might be a manifestation of diabetic nephropathy,
and that hyperglycemia or insulin deficiency possibly plays a role
in abnormal ET-1 gene regulation.
Finally, urinary endothelin excretion is increased in several
forms of renal failure, both acute and chronic, in diabetes
mellitus, and in several forms of primary glomerulonephritis.
Although it has been suggested that urinary endothelin has the
potential for serving as a marker for renal disease [145, 146], its
definitive role requires further studies.
Interactions between Ang II and ET-1
As I have extensively reviewed, mesangial cells possess recep-
tors for Ang II and ET-i, and both hormones evoke a number of
similar responses. Interactions between these peptides, therefore,
could be important for the regulation of glomerular function and
for proliferation and matrix turnover. In fact, ET-1 is produced in
cultured endothelial cells and mesangial cells after stimulation
with Ang II [147]. Angiotensin II stimulates prepro-ET-1 mRNA
in a dose- and time-dependent manner in endothelial cells [148].
The ETA receptor antagonist BQ-123 inhibited the Ang II-
induced contraction in rabbit aorta [149]. Angiotensin II also
upregulates the ETB receptors in rat cardiomyocytes [150]. Con-
versely, ET-i might affect the renin-angiotensin system, although
its role in renin release is controversial. In some studies, ET-1
increased plasma renin activity, whereas in others, a relatively low
dose of ET-1 significantly reduced renin [151—153]. When ET-1
was added to pulmonary artery endothelial cells, the conversion of
Ang Ito Ang II approximately doubled; maximal stimulation was
achieved at 10 M of ET-1. This stimulatory effect was sup-
pressed by the ACE inhibitor enalapril, but only slightly so by
nifedipine [154]. These results suggest that endothelin plays an
important role in regulating vascular tone by modulating the
conversion of Ang I to Ang II. We recently noted the same
phenomenon in cultured mesangial cells. Incubation of these cells
with ET-1 induced an increase in the conversion of Ang Ito Ang
II [121].
We have explored the hypothesis that some of the effects of
ET-i on the proliferation of mesangial cells and on extracellular
matrix protein synthesis could be due to the activation of the
renin-angiotensin system. We measured mesangial cell prolifera-
tion and production of fibronectin in response to stimulation by
108 M ET-1 and in the presence of captopril, quinaprilat, or the
Ang II receptor antagonist losartan [121]. Both ACE inhibitors
and losartan diminished mesangial cell proliferation by approxi-
mately 50% and they reduced fibronectin synthesis by 60% [121].
In isolated myocardial cells, quinapril abolished the stimulation of
protein synthesis and mRNA expression of Egr-1 induced by ET-1
[155]. Furthermore, the administration of quinapril to rats pre-
vented the hemodynamic alterations induced by the intrarenal
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injection of ET-1 [1561. Also, the decrement in renal function
observed by the infusion of systemic endothelin was markedly
attenuated in rats treated with captopril [1571. In cultured human
endothelial cells, captopril suppressed ET-1 release, probably via
a bradykinin-mediated process [158, 159]. Supporting this hypoth-
esis are recent data showing that in patients with essential
hypertension, captopril administration diminished the plasma
ET-1 concentration [160]. These data suggest that both hemody-
namic and non-hemodynamic (that is, proliferation and matrix
production) renal effects induced by ET-1 could be, at least
partially, mediated by Ang II.
In conclusion, Ang II and ET-1, well-known powerful vasocon-
strictive agents that participate in local and systemic hemody-
namic regulation, may work as growth factors and also might
increase the production of matrix proteins by mesangial and
epithelial cells and by fibroblasts. Data show that blockade of
these growth-promoting actions with ACE inhibitors and with
Ang II and ET-1 receptor antagonists has a beneficial effect in
experimental models of renal injury and in some forms of human
glomerulonephritis. Careful clinical trials are required to deter-
mine the therapeutic utility of these novel compounds.
Questions and answers
DR. LORETO GESUALDO (Institute of Nephrology, University of
Bari Ban, Italy): In your experimental model, you have shown that
there is a dramatic decrease in interstitial infiltration and tubular
atrophy in animals treated with ACE inhibitors. Do you think that
the histologic changes in your model are due to a direct effect of
angiotensin II, or are they mediated by other pathways induced by
angiotensin II, such as the chemokine system, that is, MCP-1,
IL-8, G-CSF? Can you comment on this effect?
DR. EGID0: A decrease in interstitial cell infiltration and
tubulointerstitial damage has been observed in various experi-
mental models following treatment with ACE inhibitors [reviewed
in Refs. 4, 5]. I believe that endogenous Ang II plays a role in the
pathogenetic process of renal sclerosis in those models. Several
explanations are plausible. The first idea that comes to mind in the
immune nephritis model that I presented is that the diminution in
proteinuria effected by ACE inhibitors could be a sufficient reason
for limiting the tubulointerstitial damage. However, in rats with
chronic ureteral obstruction, which develop interstitial fibrosis
without proteinuria, the ACE inhibitor was also effective in
decreasing interstitial fibrosis [102]. In this regard, systemic
infusion of Ang II for 10 to 14 days was associated with a
monocyte/macrophage influx to the kidney and further increase in
interstitial collagens and fibronectin [831. Angiotensin II and Ang
III increase chemotaxis and chemokinesis of polymorphonuclear
cells and monocytes [7, 85]. However, it is not clear whether this
increase is a direct effect or whether it is mediated through the
induction of chemokine and cytokine synthesis as you suggest.
Angiotensin II elicits in vascular smooth muscle cells and mesang-
ial cells the synthesis of PDGF, TGFI3, IL-6, and PAF, which are
chemotactic for mononuclear cells, [7, 25, 31, 162, 163]. In
preliminary results, however, Ang II induced MCP-1 gene expres-
sion in rat mesangial cells and in U937 cells (human monocytic
cell line) (unpublished results). Finally, in cultured renal intersti-
tial fibroblasts, as well as in mesangial cells, Ang II increases
extracellular matrix proteins, probably through TGF production
[31, 161].
DR. JEROME P. KASSIRER (Editor-in-Chief New England Journal
of Medicine, Boston, Massachusetts): Assuming that angiotensin II
is a potent inducer of renal fibrosis, do patients with unilateral
renal hypertension secondary to arterial stenosis have glomerular
or interstitial fibrosis in their contralateral kidney? The fact that
they do not develop a progressive reduction in function of that
kidney suggests that they do not.
DR. EGID0: Although it is true that progressive diminution in
renal function is not usually seen in patients with unilateral renal
artery stenosis and well-controlled blood pressure, the occurrence
of lesions in the non-stenotic kidney is not an exception. In early
papers on unilateral renovascular hypertension, in which bilateral
renal biopsies were performed, some degree of intrarenal vascular
disease and tubulointerstitial damage was found in the nonste-
notic kidney in virtually all of those patients [164]. Of course,
when malignant hypertension supervened in patients with renal
artery stenosis, severe arteriolar damage with fibrinoid necrosis
and tubulointerstitial damage developed in the unprotected non-
stenotic kidney [165].
Although the renin-angiotensin system's full effect on progres-
sion of renal disease is still a matter of debate, accelerated
progression was noted in the transgenic REN 2 rat model with
overexpression of the renin gene, compared with SHR rats with
similar blood pressure levels [166]. The intrarenal activation of
the renin-angiotensin system following induction of stenosis of the
renal artery is well known. The existence of renal fibrosis in the
unclipped kidney in the two-kidney, one-clip (2K-IC) model of
experimental renovascular hypertension also has been described
[841. Although a direct association between renin and fibrosis has
not been established in this model, treatment with ACE inhibitors
decreased the percentage of renal fibrosis [167]. It also is possible
that on some occasions the compensatory overproduction of
vasoactive agents such as nitric oxide and prostaglandins, which
are powerful inhibitors of cell growth and matrix protein produc-
tion, counterbalance the effects of Ang II [87, 168—171].
DR. GIUSEPPE REMUZZI (Director, Mario Negri Institute, Ber-
gamo, Italy): I would like to add that ACE-inhibition-induced
amelioration of interstitial fibrosis does not necessarily imply a
direct effect of angiotensin II on promoting interstitial fibrosis.
Actually, ACE inhibitors invariably ameliorate hydraulic perme-
ability and restore glomerular size-selective properties. The re-
sulting reduction in proteinuria prevents interstitial inflammation
and renal disease progression.
DR. TuLLI0 BERTANI (Division of Nephrology, Mario Negri
Institute): In the first part of your talk, you emphasized the effect
of ACE inhibitors in lessening both proteinuria and glomerulo-
sclerosis. What is your opinion about the relationship between
proteinuria and glomerulosclerosis?
DR. EGID0: As pointed out in previous publications on this
subject [172—174], the pathogenesis of glomerulosclerosis is a
multifactorial and complex process. The presence of filtered
protein in the tubules has been implicated in the pathogenesis of
tubulointerstitial injury, either through a direct toxic effect or
through obstruction due to the formation of intratubular casts
[172—174]. With glomerular injury, the filtered plasma proteins
may lead to local production and release of cytokines and growth
factors for tubular cells [891. As I discussed earlier, I believe that
ACE inhibitors could lessen glomerular sclerosis and tubulointer-
stitial damage by decreasing proteinuria and probably by modify-
ing the growth-promoting effect of Ang II on renal cells.
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DR. BERTANI: In adriamycin nephrosis, which probably repre-
sents one of the best experimental models of progressive glomer-
ulosclerosis, there is no evidence of glomerular hypertrophy or
proliferation of mesangial cells with overproduction of mesangial
matrix. These findings seem to suggest that glomeruloscierosis is
a very complicated issue that probably cannot be explained simply
by increased production of TGFI3 and PDGF.
DR. EGID0: I agree with you that glomerulosclerosis is a very
complicated subject and that many factors probably are impli-
cated in this phenomenon. I focused on PDGF and TGF/3 because
those two growth factors have attracted a lot of attention during
the last several years as inducers of sclerosis in various tissues.
Many other factors are indeed potential candidates for participat-
ing in the pathogenesis of glomerular and interstitial sclerosis,
including TxB2 and cytokines such as TNFcs [175, 1761. However,
it is conceivable that PDGF and TGFI3 play a key role. In the
chronic adriamycin model, an increase in renal expression and
synthesis of TGFI3 was noted coincidentally with maximal glomer-
ular and tubulointerstitial sclerosis [104]. Furthermore, TGFI3
seems to be an intermediate factor through which different
extracellular matrix inducers work. We recently noted that PAF
and immune complexes elicit the secretion of matrix proteins in
cultured mesangial cells, partially because of the generation of
TGF/3 [57, 581.
DR. ERLING B. PEDERSEN (Chief Physician, Department of Med-
icine and Nephrology, University Hospital, Aarhus, Denmark): Pa-
tients with Bartter's syndrome have a very high angiotensin II
level for many years, but they don't have progressive renal failure
and fibrosis. How does this fit your hypothesis?
DR. EGIDO: As you know, patients with Bartter's syndrome
feature severe hypokalemia due to renal potassium wasting, with
hyperplasia of the juxtaglomerular apparatus, hyperreninemia,
and hyperaldosteronism. These patients also have an impaired
pressor response to Ang II. In fact, they are normotensive and
have renal overproduction of prostaglandins [177]. Although
speculative, it is possible that in this syndrome renal cells cannot
respond in an appropriate manner, that is, with cell growth and
matrix protein synthesis, to the augmented generation of Ang II.
In fact, an abnormality in the AT1 receptor gene recently was
found in one of five patients with Bartter's syndrome [178]; this
alteration probably indicates the existence of subsets of patients
with this disease. The increased production of prostaglandins and
potentially other vasoactive agents could also counterbalance the
effects of Ang II [87, 168—171, 179].
An increase in the expression and synthesis of various compo-
nents of the renin-angiotensin system has been observed in
different renal pathophysiologic situations, such as salt depletion,
nephrotic syndrome, high protein intake and uninephrectomy,
obstructive nephropathy, diabetic nephropathy, and others [re-
viewed in Ref. 91]. The reason for the absence in the kidney of
apparent growth-promoting consequences of Ang II in some of
those circumstances remains unclear. Indeed, in tissue culture
studies, Ang II per se is a relatively weak mitogen. It is possible
that the local activation of other mediators, such as cytokines,
growth factors, and bioactive lipids, exert additive effects on the
role of Ang II in cell proliferation and in matrix protein synthesis.
DR. PEDERSEN: Does a reduction in proteinuria per se to the
non-nephrotic range, like that occurring after ACE inhibition and
after the administration of nonsteroidal antiinfiammatory drugs,
reduce the progression of renal disease?
DR. EGIDO: It is generally assumed that in chronic glomerular
diseases, the severity and persistence of proteinuria are key
factors in the progression to renal failure. Multivariate statistical
analysis has confirmed that heavy proteinuria is one of the most
powerful independent prognostic indicators in several glomerular
and nonglomerular diseases [180]. In addition to being considered
a marker of the severity of renal damage, persistent proteinuria
actually might cause progressive damage of glomerular epithelial
cells and might be directly responsible for the tubulointerstitial
damage associated with many glomerular diseases [1721. The
reduction of proteinuria levels to the non-nephrotic range by ACE
inhibitor therapy is accompanied by a positive effect on hyperlip-
idemia, a widely accepted risk factor for the development of
glomerulosclerosis.
In patients with diabetic nephropathy, a reduction in albumin-
uria attenuates progression of renal dysfunction and reduces
mortality [6, 75]. A relationship between an increase in protein-
uria and an expansion of mesangial volume is well documented in
experimental models of diabetes. The administration of ACE
inhibitors to uninephrectomized dogs with diabetic nephropathy
attenuated the rise in proteinuria, the development of focal
glomerulosclerosis, and the expansion of mesangial volume [181].
DR. FRANCESCO PAOLO SCHENA (Chairman, Institute of Nephrol-
ogy, University of Ban): You mentioned a possible relationship
between endothelin and cytokines. In the last few years, some
investigators have demonstrated that IL-6 levels are an index of a
poor prognosis, as IL-6 is produced by infiltrating cells and
tubular cells in advanced renal damage. Do you have data
concerning the interrelationship between endothelin and IL-6?
DR. EGID0: The relationship between endothelin and cytokines
is dual. Several renal cells secrete ET-1 under the stimulation
of TGFI3, PDGF, TNFa, and IL-1/3 [111, 114, 131, 132, 182].
Moreover, ET-1 induces the expression and synthesis of various
cytokines in mesangial cells [14, 15, 1761. Recent data have shown
that ET-1, as well as other vasoconstrictors such as Ang II and
arginine vasopressin, elicit the synthesis of IL-6 in mouse mesang-
ial cells [162]. Therefore, it is possible that some of the effects of
ET-1 on cell growth could be due to the release of cytokines like
IL-6.
DR. SANDOR S0NK0DI (Head, Nephrology Section, Albert Szent-
Gyorgyi Medical University, Szeged, Hungary): You mentioned that
the 5/6th nephrectomy model developed proteinuria and renal
sclerosis after just one week and that ACE inhibitors can alter
disease progression in that model. It is important for us to know
which 5/6th nephrectomy model was used, the ligation model, in
which 2 of the 3 arterial branches are tied, or the ablation model,
in which one removes the upper and lower poles of the kidney?
DR. EGIDO: The remnant kidney model induced by 5/6th
nephrectomy is probably the most extensively studied model of
progressive glomerular disease. Under the heading of this term
there are at least three different models: Unilateral nephrectomy
plus pole resection, arterial branch ligation, or pole ligation in the
other kidney [60, 183]. Although all three models are character-
ized by proteinuria, hypertension, and the loss of renal function,
the elevation of blood pressure is earlier and more evident in the
arterial branch ligation and in the pole ligation models than in the
pole resection model. Proteinuria and progressive loss of renal
function appear in each of the three models by 3 to 4 weeks after
surgery [183]. In my presentation I referred to the arterial branch
ligation model because it is probably the most commonly used.
Nephrology Forum: Vasoactive hormones and renal sclerosis 589
DR. S0NK0DI: The ACE inhibitor produces the same beneficial
effects on proteinuria in both models, but in the ablation model,
the renin-angiotensin system is not activated, and the sclerosis is
not evident alter 6 weeks. Would you comment on this?
DR. EOID0: A thorough comparative study of the renin-angio-
tensin system in the three different remnant kidney models has
not been done. Plasma-renin activity was lowest in the pole
resection model, intermediate in the branch ligation model, and
highest in the pole ligation model [183]. Renal renin mRNA
abundance and renin activity were not increased in the remnant
kidney model following subtotal nephrectomy and pole ligation,
when compared with sham-operated controls [184]. This finding
contrasts sharply with the excellent response of proteinuria and
glomerular injury to ACE inhibitors in that model [62]. Several
explanations for this apparent paradox, that is, normal values of
renal RAS and good response to ACE inhibitors, have been
advanced [91]. Alterations in the distribution of RAS components
within the kidney could result in local areas of activation of this
system, which could not be detected by the study of the whole
organ [184]. In fact, in this model an accumulation of renin within
glomeruli and in tissue adjacent to the infarcted scar has been
shown [185]. Similarly, the renin content of residual nephrons
could be higher than that of controls in this model.
DR. DoNTscHo KERJA5CHKI (Professor of Pathology, University of
Vienna, Vienna, Austria): Could the effect of ACE inhibitors in the
immune-complex model work via oxygen radical scavenger inhi-
bition? Could oxygen radical scavenger inhibitors show the same
protective effects?
DR. EGID0: Free radicals and reactive oxygen molecules play a
role in the pathogenesis of several diseases including glomerulo-
nephritis [186]. In fact, reactive oxygen molecules may be the final
common mediator of tissue injury in many circumstances. Because
of its sulfhydryl group, captopril might be a scavenger of reactive
oxygen molecules [187, 188]. In one study, captopril preserved
renal structure and function better than enalapril, which does not
contain a sulthydryl group [187]. Recent evidence has shown that
captopril also scavenges hydrogen peroxide and reduces, but does
not eliminate, oxidant-induced injury in human renal tubular
epithelial cells [188]. Although daily administration of superoxide
dismutase significantly suppresses urinary albumin excretion in
Wistar rats with serum sickness nephritis [186], the beneficial
effect obtained with quinapril in the model of immune nephritis
used seems independent of reactive oxygen molecules, since that
ACE inhibitor does not contain a sulfhydryl group [189].
DR. JEAN-PIERRE GRUNFELD (Division of Nephrology, Hôpital
Necker, Paris, France): Weber and Brilla suggested that, in
addition to angiotensin II, aldosterone could trigger cardiac
fibrosis [190]. Are you aware of experimental data showing that
aldosterone also could be involved in promoting renal interstitial
fibrosis?
DR. EGID0: In rat models of primary or secondary hyperaldo-
steronism, myocardial fibrosis was found in the hypertrophied left
ventricle; this fibrosis was prevented by the aldosterone receptor
antagonist spironolactone [191]. In cultured cardiac fibroblasts,
aldosterone stimulates collagen gene expression [190]. Recent
data suggest that locally produced aldosterone in the vascular
endothelial cells induces hypertrophy in vascular smooth muscle
cells [192, 193]. To my knowledge, however, there is no direct
evidence that aldosterone promotes renal interstitial fibrosis.
DR. GRUNFELD: Is it possible to compare cardiac fibrosis with
renal fibrosis or liver fibrosis?
DR. EGID0: Fibrogenesis can be viewed as an aberrant exten-
sion of normal regulatory events operating during the turnover of
cellular components and extracellular matrix [194]. Renal and
cardiac interstitial fibroblasts mediate both production and deg-
radation of the structural proteins collagen and elastin in the
interstitium [190, 194]. Fibroblasts are pluripotential cells that are
particularly sensitive to factors elaborated by mononuclear cells
and are free to move within the extracellular space. They contain
messenger RNA for type-I and type-Ill collagens, the major
fibrillar collagens of the myocardium and the kidney, which
constitute the normal structural protein network of these organs.
These collagens also are involved in the interstitial fibrosis of the
myocardium and the kidney [190, 194]. Although many details of
the complex process of renal fibrogenesis remain to be elucidated,
several general features of this phenomenon are probably shared
by other organs such as heart, liver, lung, and skin [194].
DR. DANIEL CORDONNIER (Centre Hospitalier Universitaire,
Grenoble, France): I would like to address the question of the
dose-dependent effectiveness of ACE inhibitors on renal, and
especially interstitial, lesions and on cytokines. It is my under-
standing that the effectiveness of ACE inhibitors is clearly not
related to the proteinuria level. If that is true, how far should one
augment the dose of ACE inhibitors in animals and in humans? Is
this additional effect directly or indirectly related to the effect of
angiotensin II on the cytokines and matrix proteins?
DR. EGID0: The different effects on proteinuria of different
doses of ACE inhibitors are clearly exemplified in the studies of
the non-hypertensive model of puromycin nephrosis. Early re-
ports showed that in rats, the so-called low dose of ACE inhibitor,
that is, enalapril, 50 mg/liter drinking water, did not attenuate
massive proteinuria in the acute nephrotic stage [195]. However,
in further studies, higher doses of enalapril (200 mg/liter) did
reduce proteinuria in the same model [196]. The greater benefi-
cial effect of higher doses of ACE inhibitor also was observed in
studies on structural injury in the remnant kidney model. Al-
though low and high doses of ACE inhibitors were equipotent in
terms of control of the elevated systemic and glomerular pres-
sures, the higher dose induced a more marked diminution in the
percentage of sclerotic glomeruli and mesangial matrix expansion
[197].
If we assume that Ang II is a growth factor for various renal
cells, the prolonged inhibition of tissue ACE might be important
at the kidney level. The effects of Ang II on the kidney are
critically concentration-dependent [17]. Tissue ACE is much
more difficult to inhibit than serum ACE [67, 198]. In this regard,
one of the most pressing current issues in the ACE inhibitor field
is to determine whether the different members of this family have
specific cardiac, arterial, or renal actions that can produce further
benefit beyond the blood pressure lowering effect [199]. In this
context, some of these drugs, such as quinapril which we used in
our experimental model, are tightly bound to tissue ACE, thereby
resulting in prolonged inhibition [199].
DR. L. A. VAN Es (Department of Nephrology, Leiden University,
Leiden, The Netherlands): Are renal fibroblasts mainly responsible
for interstitial fibrosis? How are these fibroblasts characterized?
DR. EGID0: In the kidney, as in other organs, fibroblasts are
probably the most important cells participating in the process of
interstitial fibrosis [89, 190]. But other cells, such as tubular
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epithelial cells and vascular endothelial cells, may act as targets
for inflammatory mediators (cytokines and growth factors) and
can synthesize, in turn, more cytokines and extracellular matrix in
the renal interstitium [1941.
In most studies, fibroblast cell lines from the tubulointerstitium
of mice, rats, and humans were established as primary cultures
[200—203]. Those cells seem to have attributes of fibroblasts such
as positive staining for vimentin and actin, and morphologic and
collagen secretory profiles similar to those of prototypic generic
fibroblasts [200—203]. I agree, however, that those criteria are far
from being definitive in defining true fibroblasts.
DR. KARL M. KOCH (Professor of Medicine, Medizinische
Hochschule, Hannover, Germany): Dr. Mueller from Goettingen
showed that cells, which he thinks are fibroblasts, grow out of
cultured biopsies from human kidneys with chronic glomerulo-
nephritis and interstitial fibrosis, but not from tissue obtained
from normal kidneys. This finding, as yet unpublished, indeed
indicates that these presumed fibroblasts in renal interstitial
fibrosis are in an actively proliferative state.
DR. ARTURO BORSATTI (Professor of Nephrology, University of
Padova, Padova, Italy): Both angiotensin II and endothelin in-
crease the production of nitric oxide, which has an antiprolifera-
tive effect on renal cells. Do you think nitric oxide could play a
role in your hypothetical system?
DR. EGID0: ACE inhibitors might have additional actions apart
from the diminution of Ang II generation. In blood vessels,
bradykinin accumulates after ACE inhibition [204]. Bradykinin
seems to be a potent stimulus for nitric oxide and prostaglandin '2
release from the endothelium [205]. Recent data suggest that
nitric oxide modulates cell growth and the synthesis of extracel-
lular matrix proteins in cultured mesangial and vascular smooth
muscle cells [87, 168—170]. Therefore, we cannot discard the
possibility that a part of the ACE inhibitor's action is mediated by
the bradykinin-nitric oxide pathway. At least in the model of renal
mass ablation, however, the employment of an AT1 receptor
antagonist exerted a reduction in proteinuria and glomerular
sclerosis similar to that of an ACE inhibitor [77, 78].
DR. ALEX M. DAvIsoN (Consultant Renal Physician, St. James's
University Hospital, Leeds, UK): I'd like to return to the clinical
situation. There does not seem to be a close linear relationship
between proteinuria and progression to renal failure, as it appears
that "heavy" proteinuria for a prolonged period is required to
produce functional impairment. At what degree of proteinuria
should ACE inhibition be started, and by how much should
proteinuria be reduced to have a beneficial clinical effect?
DR. EGID0: The harmful effects of persistent proteinuria have
been previously pointed out. The loss of renal function is much
more rapid in proteinuric than in nonproteinuric renal disease
[180]. Furthermore, in diabetic renal disease, proteinuria is a
predictor of ultimate renal function [206]. Otherwise, in asymp-
tomatic patients with isolated non-nephrotic proteinuria of less
than 2 glday, there is little evidence in the literature suggesting
that the disease will progress to renal failure [207].
In patients with primary glomerular diseases, treatment with
ACE inhibitors usually has been initiated when proteinuria was in
the nephrotic range, although some patients with proteinuria
around 2 g or less have also been treated with these medications
[5, 6, 72]. Interestingly, the U.S. Modification of Diet in Renal
Disease (MDRD) study showed that, in patients with renal
disease causing proteinuria  1 g/day, the decline in GFR was
significantly correlated with the level of control of systolic blood
pressure [208]. The loss of GFR was significantly more rapid in
patients whose systolic blood pressure was approximately 135 mm
Hg than in those whose systolic blood pressure was approximately
125 mm Hg [208].
Thus, although more experience and longer followup are
needed, I am tempted to recommend that we treat patients who
have glomerular disease and proteinuria exceeding 1 glday, aim-
ing at values of systolic blood pressure of about 125 mm Hg [208].
DR. REMuzzI: Concerning the point raised by Dr. Davison on
how soon to start ACE inhibitors to reduce proteinuria and
prevent progression, I would like to refer to a recent study from
the U.S. published in the American Journal of Kidney Disease,
showing that in type-lI diabetics who were given ACE inhibitors in
the early phase of nephropathy, when they had microalbuminuria,
after one year of treatment microalbuminuria stabilized, and GFR
(measured as inulin clearance) was 20% higher than it had been
before the treatment had begun [209].
DR. JOHN T. HARRINGTON (Dean for Academic Affairs, Tufts
University School of Medicine, Boston, Massachusetts): More than
25 years ago, we showed that the level of proteinuria correlated
very well with outcome in patients with nephrotic syndrome of
diverse type. Renal function remained normal or stable in patients
with less than 2.0 g/day of proteinuria, whereas renal function
deteriorated in approximately one-half of those with greater than
2.0 g/day of proteinuria [210]. These data might be helpful in
answering Dr. Davison's question.
DR. PANOS N. ZIROYANIS (Director of Nephrology, General
Hospital, Athens, Greece): Do you have data concerning any
contributory role of advanced glycosylation end products in the
development of fibrosis? As you know, one of the functions of
these products is to stimulate the secretion of growth factors.
DR. EGID0: As is well known, one of the consequences of
hyperglycemia is the formation of advanced glycosylation end
products, that is, AGEs. Specific receptors for AGEs are present
in several cell types, including human and rat mesangial cells. The
exposure of those cells to AGEs increased the gene expression of
several extracellular matrix proteins such as fibronectin, collagen
type-IV, laminin, and heparan sulfate proteoglycans [2111. As you
point out, PDGF seems to act as an intermediate factor. Fibro-
blast AGE receptors also might influence cellular proliferation
[212]. These data suggest that AGE formation in vivo might be
one of the metabolic events leading to the development of
diabetic glomerulosclerosis.
DR. FERNANDO VALDERRABANO (Chairman, Department of
Nephrology, Hospital General Universitario Gregorio Marañon,
Madrid, Spain): Angiotensin-converting-enzyme inhibitors worsen
anemia in patients with chronic renal failure. It has been postu-
lated that angiotensin II stimulates, and ACE inhibitors dampen,
erythropoietin production [213—215]. Do you have any explana-
tion for the mechanism of stimulation by angiotensin II of
peritubular cells, which produce erythropoietin? Is it a hemody-
namic or a direct effect?
DR. EGIDO: The renin-angiotensin system affects both erythro-
poietin synthesis and hemoglobin concentration. The administra-
tion of ACE inhibitors to healthy volunteers significantly reduced
the mean plasma erythropoietin concentration, its level returning
to baseline after the drugs were discontinued [214]. Captopril, at
low dose, was an effective therapy for post-transplant erythrocy-
tosis [216]. In patients with unilateral renal artery stenosis, ACE
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inhibition normalized the veno-arterial gradient of erythropoietin;
this finding suggests that the renin-angiotensin system is impor-
tant for erythropoietin production in the affected kidney in
unilateral renal disease [215]. To my knowledge there is no
convincing evidence that Ang II could directly induce the secre-
tion of erythropoietin, but it could be the case.
DR. NIcoLAos E. MADIAS (Chief Division of Nephrology, New
England Medical Center, Boston): Do vasoactive hormones affect
the degradation of extracellular matrix proteins in addition to
influencing their synthesis?
DR. EGID0: Most of the studies on the potential effect of
vasoactive hormones on degradation of extracellular matrix pro-
teins have been done in cardiac fibroblasts. In those cells, both
ET-1 and Ang II directly stimulated collagen synthesis and
inhibited collagenase activity, the key enzyme for collagen degra-
dation, effects that would lead to collagen accumulation [217—
220]. Surprisingly, few data exist about the effects of such hor-
mones on matrix proteolytic enzymes in renal cells. In mesangial
cells, ET-1 but not ET-3 increases collagenase gene expression
[220]. Angiotensin II also could modify the matrix protein turn-
over through the induction of expression and synthesis of TGF/3,
as it has been demonstrated in cultured vascular smooth muscle
cells and in mesangial cells [27, 31]. Besides triggering the
synthesis of numerous matrix proteins, TGF decreases matrix
degradation by downregulation of proteases and induction of
protease inhibitors [221].
DR. KOSTAS C. SIAMoPouLos (Associate Professor of Medicine!
Nephrology, University Hospital of Joannina, loannina, Greece):
You mentioned that the higher the dose of ACE inhibitor, the
more likely that proteinuria will respond to therapy. Does this
mean that the circulating renin-angiotensin II system is more
important than the local system for the renal lesions?
DR. EGID0: I believe that the local renin-angiotensin system is
more important than the circulating one in the pathogenesis of
renal lesions. Arai et al recently found, 7 days after transfection of
human genes for renin and angiotensinogen into the rat kidney,
an expansion in the glomerular extracellular matrix and pheno-
typic changes of the mesangial cells [222]. In our rats with
immune-complex nephritis, the administration of quinapril (100
mg/liter drinking water) diminished plasma ACE activity by more
than 90%, contrasting with a decrease of only 50% to 60% in renal
ACE activity; this change is in accordance with that observed in
rat vessels when the same dose of quinapril was used [198]. As I
mentioned earlier, the concentration of Ang II is one thousand
times higher in the kidney than in plasma [17]. It is therefore
possible that higher doses of ACE inhibitor further decrease the
generation of local Ang II and can prevent in a more effective
manner the consequences of this hormone on renal circulation,
cell growth, and extracellular matrix synthesis.
DR. LANDINO ALLEGRI (Institute of Medicine and Nephrology,
University of Parma, Parma, Italy): Can we suppose even an
indirect action of vasoactive hormones in renal matrix synthesis
and sclerosis production that is mediated by facilitating the
formation of immune complexes at the renal level?
DR. EGID0: Ten years ago, Keane and Raij demonstrated that
Ang II affects mesangial trafficking and leads to an increased
uptake of macromolecules in the mesangium, which may predis-
pose to eventual glomerular sclerosis [223]. Recent evidence from
our laboratory has shown that in vitro, immune complexes,
through Fe receptors, directly stimulate rat and human mesangial
cells to produce extracellular matrix proteins [57]. However, in
our model of proliferative nephritis in rats, the administration of
ACE inhibitors did not decrease the amount of immune com-
plexes in the glomerular area. Therefore, the vasoactive hormones
cannot play an important role in the formation of complexes at
the renal level.
DR. HARRINGTON: Can you block the nonhemodynamic effects
of angiotensin II without blocking the hemodynamic effects? If so,
what happens? More specifically, can you block cell matrix protein
production without blocking the renal hemodynamic effects of
angiotensin II?
DR. EGID0: This is an interesting question that has no simple
answer. Molecular biology studies have shown that all renin-
angiotensin system components are present in cells, both in the
cortex and medulla of human kidneys [18]. Renin and ACE
activity also varies from one renal zone to another [224]. It is
therefore possible that with a particular dose of an ACE inhibitor,
a certain decrease in the generation of Ang II occurs in different
renal cells. Indeed, in the remnant kidney model, the administra-
tion of a low and high dose of enalapril (50 mg/liter versus 200
mg/liter drinking water) decreased in a comparable manner the
systemic and glomerular blood pressures, even though the bene-
ficial effect on sclerosis index and mesangial matrix expansion was
greater in the higher ACE inhibitor dose [196]. Furthermore, in
the stroke-prone spontaneously hypertensive rats, despite the fact
that low doses of an AT1 receptor antagonist did not induce a
decrease in blood pressure, Kim et al noted a significant inhibition
in the gene expression of renal TGFf3 and in extracellular matrix
proteins [2251.
One is tempted to speculate that glomerular hemodynamic
alterations are more easily reversed by ACE inhibitors or AT1
receptor antagonists than are the nonhemodynamic effects. We
should remember, however, that glomerular hypertension stimu-
lates extracellular matrix formation in rat glomeruli [34].
DR. KASSIRER: Dr. Davison's question raises an important issue
addressed here only minimally, namely, why we do not have
answers to straightforward clinical questions. I believe that, in
contrast to the community of oncologists and cardiologists, for
example, nephrologists have mounted too few large controlled
trials to answer such questions. Many clinical trials in nephrology
involve only a small number of patients or end points that are not
definitive. We thus continue to ask questions rather than provide
real answers about the care of patients with renal diseases.
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